- Home
- BAH vs PTGX Comparison
BAH vs PTGX Comparison
Compare BAH & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BAH | PTGX |
|---|---|---|
| Founded | 1914 | 2006 |
| Country | United States | United States |
| Employees | 31500 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 9.3B |
| IPO Year | 2010 | 2016 |
Fundamental Metrics
Financial Performance| Metric | BAH | PTGX |
|---|---|---|
| Price | $73.20 | $146.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | $97.00 | ★ $108.23 |
| AVG Volume (30 Days) | ★ 1.5M | 454.1K |
| Earning Date | 05-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.09% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.63 | ★ 2.35 |
| Revenue | ★ $11,217,000,000.00 | N/A |
| Revenue This Year | N/A | $874.25 |
| Revenue Next Year | $2.14 | N/A |
| P/E Ratio | ★ $46.25 | $62.34 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $59.50 | $57.45 |
| 52 Week High | $109.10 | $160.81 |
Technical Indicators
Market Signals| Indicator | BAH | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 46.59 | 50.07 |
| Support Level | $68.84 | $127.98 |
| Resistance Level | $80.91 | $160.81 |
| Average True Range (ATR) | 2.24 | 5.78 |
| MACD | -0.58 | -1.71 |
| Stochastic Oscillator | 1.71 | 21.64 |
Price Performance
Historical ComparisonAbout BAH Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp provides technology solutions in areas such as artificial intelligence, cybersecurity, and related fields. The company serves U.S. federal government agencies, commercial clients, and select international customers. It also provides technologies to evolve defense missions and delivers solutions to warfighters in the digital battlespace.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.